<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83092">
  <stage>Registered</stage>
  <submitdate>19/08/2008</submitdate>
  <approvaldate>26/10/2009</approvaldate>
  <actrnumber>ACTRN12609000916246</actrnumber>
  <trial_identification>
    <studytitle>A prospective study assessing the predictive value of testing stool for blood  prior to capsule endoscopy for the investigation of iron deficiency anaemia or obscure gastrointestinal bleeding</studytitle>
    <scientifictitle>A prospective study assessing the predictive value of faecal occult blood testing prior to capsule endoscopy for the investigation of iron deficiency anaemia or obscure gastrointestinal bleeding</scientifictitle>
    <utrn />
    <trialacronym>FINCE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Obscure Gastrointestinal Bleeding</healthcondition>
    <healthcondition>Iron deficiency Anaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients referred for capsule endoscopy will undergo two faecal occult blood tests (FOBT) within two weeks prior to the capsule endoscopy.  The results of the FOBT will be correlated with clinically significant findings on the capsule endoscopy, to assess whether there is a correlation between the two.</interventions>
    <comparator>The yield of clinically significant findings on capsule endoscopy will be compared in patients with positive FOBT and those with negative FOBT, to calculate the negative and positive predictive values of FOBT for significant findings on capsule endoscopy.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The predictive value of a positive FOBT for a clinically significant findings on capsule endoscopy.

The yield of clinically significant findings on capsule endoscopy will be compared in patients with positive FOBT and those with negative FOBT, to calculate the negative and positive predictive values of FOBT for significant findings on capsule endoscopy.</outcome>
      <timepoint>The results of the FOBT will be collected once the results of the capsule endoscopy have been verified (within 1-2 weeks of the capsule endoscopy).  Statistical analysis will occur at the conclusion of the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult &gt; 18years
Clinically accepted indication for capsule endoscopy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Documented small intestinal stricture
History of recurrent small bowel obstruction
Allergy or contraindication to picoprep or alternative bowel preparation regimens.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital - Melbourne</primarysponsorname>
    <primarysponsoraddress>35 Fitzroy St, Fitzroy, Victoria 3065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincent's Hospital - Melbourne</fundingname>
      <fundingaddress>35 Fitzroy St, Fitzroy, Victoria 3065</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of the study is to test whether a faecal test done before capsule endoscopy can identify those patients that are likely to have a significant result on the capsule endoscopy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research and Ethics Committee (HREC)</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/07/2009</ethicapprovaldate>
      <hrec>1/08/0086</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Marios Efthymiou</name>
      <address>35 Fitzroy St, Fitzroy, Victoria 3065</address>
      <phone>+61392882211</phone>
      <fax>+61386781032</fax>
      <email>marios.efthymiou@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Marios Efthymiou</name>
      <address>35 Fitzroy St, Fitzroy, Victoria 3065</address>
      <phone>+61392882211</phone>
      <fax>+61386781032</fax>
      <email>marios.efthymiou@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Marios Efthymiou</name>
      <address>35 Fitzroy St, Fitzroy, Victoria 3065</address>
      <phone>+61392882211</phone>
      <fax>+61386781032</fax>
      <email>marios.efthymiou@svhm.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>